Key terms
About RNA
Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). It utilizes its AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. The company was founded by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick on November 13, 2012 and is headquartered in San Diego, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest RNA news
Apr 02
4:19pm ET
Avidity Biosciences files to sell 24.26M shares of common stock for holders
Mar 06
11:25pm ET
Avidity Biosciences: Strong Buy Rating Amidst Positive Clinical Developments and Price Target Surge
Mar 06
11:33am ET
Dyne Therapeutics price target raised to $37 from $33 at Guggenheim
Mar 05
5:02am ET
Optimistic Buy Rating for Avidity Biosciences Backed by Promising Phase 3 Study Design and Positive MARINA OLE Data
Mar 05
5:01am ET
Analysts’ Top Healthcare Picks: Avidity Biosciences (RNA), Irhythm Technologies (IRTC)
Mar 04
9:36pm ET
Buy Rating Affirmed for Avidity Biosciences Following Promising MARINA-OLE Study Data and RNA Analysis
Mar 04
9:32pm ET
Avidity Biosciences price target raised to $33 from $23 at Chardan
Mar 04
7:03am ET
Avidity Biosciences announces ‘positive’ data from MARINA-OLE trial
Feb 29
4:24pm ET
Avidity Biosciences Launches Major Stock and Warrants Placement
Feb 29
7:11am ET
Analysts Are Bullish on These Healthcare Stocks: Avidity Biosciences (RNA), Revance Therapeutics (RVNC)
Feb 29
7:04am ET
Avidity Biosciences sells 15.22M shares at $16.50 in private placement
Feb 29
5:39am ET
Avidity Biosciences: A Strong Buy on Promising Drug Candidate and Strategic Trial Design
Feb 29
1:49am ET
3 Best Stocks to Buy Now, 2/29/2024, According to Top Analysts
Feb 28
10:05pm ET
TD Cowen Reaffirms Their Buy Rating on Avidity Biosciences (RNA)
Feb 28
5:40pm ET
Avidity Biosciences files to sell 5.075M shares of common stock for holders
Feb 28
4:09pm ET
Avidity Biosciences reports Q4 EPS (79c), consensus (66c)
Feb 20
9:04am ET
Avidity Biosciences’ candidate for DMD designated Rare Pediatric Disease by FDA
Feb 02
8:52am ET
Chardan lays out top 4 biotech picks for 2024
Jan 10
5:41am ET
Buy Rating on Avidity Biosciences Amid Promising Clinical Milestones
Jan 04
4:40am ET
Avidity Biosciences: A Strong Buy on Cross-Validated Myotonia Reduction and Promising Treatment Durability
No recent press releases are available for RNA
RNA Financials
Key terms
Ad Feedback
RNA Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
RNA Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
